Compugen Ltd. ( NASDAQ: CGEN) today announced that it will present at the Immunology 2014 Conference to be held May 2-6 in Pittsburgh. Immunology 2014, the annual meeting of the American Association of Immunologists, is a premier international scientific meeting at which world leaders in immunology present their research. Compugen’s presentation will take place in a session entitled “Harnessing Cellular and Molecular Interactions in Autoimmunity” on Tuesday, May 6, 2014. In her presentation, Iris Hecht, PhD, Principal Scientist at Compugen, will review results for CGEN-15001, an Fc fusion protein based on one of the immune checkpoint candidates discovered by the Company. These results for CGEN-15001, obtained in in-vitro systems and multiple models of autoimmune diseases, demonstrate this product candidate’s efficacy and unique mode-of-action, including promotion of regulatory T cells and its potential for induction of long-term immune tolerance. Immune tolerance induction is a highly sought-after approach for treatment of autoimmune diseases, such as type 1 diabetes, rheumatoid arthritis and multiple sclerosis. The results being presented by Dr. Hecht include data from Compugen’s long-standing collaboration with Stephen Miller, Judy Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine. Compugen also announced today that the scope of this collaboration has been expanded to now include activities to further characterize the immune function of a number of Compugen-discovered checkpoint target candidates, in addition to further studies involving CGEN-15001. The CGEN-15001 studies will address its potential for ameliorating autoimmunity through the induction of immune tolerance, and will include translational research using biological samples from autoimmune patients. Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, “We are pleased to participate in this important conference to be attended by world leading researchers in the field of immunology. Our participation will take the form of both a poster and an oral presentation reviewing the promising results for CGEN-15001, our leading candidate for therapeutic use in immunology. Looking ahead, we expect that the extended long-term collaboration with Professor Miller and Northwestern University will further demonstrate the unique therapeutic potential of this candidate for treatment of multiple autoimmune diseases, as well as advance the research and validation of a number of other Compugen discovered immune checkpoint target candidates.”
The scientific poster accompanying Compugen’s Immunology 2014 Conference presentation will be available at the Company’s website following the conference.About Compugen Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. Forward-looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which may include words such as “may,” “expects,” “anticipates,” “potential,” “believes,” and “intends,” and describe opinions about future events. Forward-looking statements in this press release include, but are not limited to, statements relating to CGEN-15001’s potential for ameliorating autoimmunity through the induction of immune tolerance and for treatment of multiple autoimmune diseases, that the planned research activities under the expanded relationship with Northwestern University Feinberg School of Medicine will be undertaken or if undertaken will be successful, and the expected advancement of the research for a number of other Compugen discovered checkpoint target candidates. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks and other factors are discussed in the "Risk Factors" section of Compugen’s Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.